TY  - JOUR
AU  - Krampitz, G.W.*
AU  - Tsai, J.*
AU  - Norton, J.A.*
AU  - Weissman, I.L.*
AU  - Rinkevich, Y.
C1  - 55622
C2  - 46410
CY  - 233 Spring St, New York, Ny 10013 Usa
SP  - S192-S192
TI  - Adhesions are derived from hypoxia responsive mesothelin-positive mesothelial cells and are resolved via targeted therapies.
JO  - Ann. Surg. Oncol.
VL  - 26
PB  - Springer
PY  - 2019
SN  - 1068-9265
ER  - 

TY  - JOUR
AB  - Due to a metadata tagging error the names of Stephanie E. Combs and Jan S. Kirschke were indexed incorrectly. Stephanie E. is the author’s given name, and Jan S. is the author’s given name.
AU  - Bette, S.*
AU  - Barz, M.*
AU  - Wiestler, B.*
AU  - Huber, T.*
AU  - Gerhardt, J.*
AU  - Buchmann, N.*
AU  - Combs, S.E.
AU  - Schmidt-Graf, F.*
AU  - Delbridge, C.*
AU  - Zimmer, C.*
AU  - Kirschke, J.S.*
AU  - Meyer, B.*
AU  - Ryang, Y.M.*
AU  - Ringel, F.*
AU  - Gempt, J.*
C1  - 53351
C2  - 44717
CY  - 233 Spring St, New York, Ny 10013 Usa
SP  - 989-989
TI  - Prognostic value of tumor volume in glioblastoma patients: Size also matters for patients with incomplete resection (vol 25, pg 558, 2018).
JO  - Ann. Surg. Oncol.
VL  - 25
PB  - Springer
PY  - 2018
SN  - 1068-9265
ER  - 

TY  - JOUR
AB  - Incomplete resection of glioblastoma is discussed controversially in the era of combined radiochemotherapy. The aim of this study was to analyze the benefit of subtotal tumor resection for glioblastoma patients as this was recently questioned in the era of radiochemotherapy. Overall, 209 patients undergoing surgery for newly diagnosed WHO grade IV gliomas were retrospectively analyzed, and pre- and postoperative tumor volumes were manually segmented (cm(3)). Survival analyses were performed, including prognostic factors such as age, Karnofsky performance score (KPS), O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, and adjuvant treatment regimen. Pre- and postoperative tumor volume is significantly associated with pre- and postoperative KPS, as well as age (p < 0.001). Postoperative tumor volume remained a significant prognostic factor in a multivariate analysis, independent of other prognostic factors (hazard ratio 1.0365, 95% confidence interval 1.0235-1.0497, p < 0.001). In the era of molecularly-driven radiochemotherapy, glioblastoma surgery remains a major prognostic factor. Even in situations in which a gross total resection cannot be achieved, maximum safe reduction of tumor burden should be attempted.
AU  - Bette, S.*
AU  - Barz, M.*
AU  - Wiestler, B.*
AU  - Huber, T.*
AU  - Gerhardt, J.*
AU  - Buchmann, N.*
AU  - Combs, S.E.
AU  - Schmidt-Graf, F.*
AU  - Delbridge, C.*
AU  - Zimmer, C.*
AU  - Kirschke, J.S.*
AU  - Meyer, B.*
AU  - Ryang, Y.M.*
AU  - Ringel, F.*
AU  - Gempt, J.*
C1  - 52460
C2  - 43991
CY  - New York
SP  - 1-7
TI  - Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.
JO  - Ann. Surg. Oncol.
VL  - 25
IS  - 2
PB  - Springer
PY  - 2017
SN  - 1068-9265
ER  - 

TY  - JOUR
AB  - BACKGROUND: This study was designed to improve the surgical procedure and outcome of cancer surgery by means of real-time molecular imaging feedback of tumor spread and margin delineation using targeted near-infrared fluorescent probes with specificity to tumor biomarkers. Surgical excision of cancer often is confronted with difficulties in the identification of cancer spread and the accurate delineation of tumor margins. Currently, the assessment of tumor borders is afforded by postoperative pathology or, less reliably, intraoperative frozen sectioning. Fluorescence imaging is a natural modality for intraoperative use by directly relating to the surgeon's vision and offers highly attractive characteristics, such as high-resolution, sensitivity, and portability. Via the use of targeted probes it also becomes highly tumor-specific and can lead to significant improvements in surgical procedures and outcome. METHODS: Mice bearing xenograft human tumors were injected with α(v)β(3)-integrin receptor-targeted fluorescent probe and in vivo visualized by using a novel, real-time, multispectral fluorescence imaging system. Confirmatory ex vivo imaging, bioluminescence imaging, and histopathology were used to validate the in vivo findings. RESULTS: Fluorescence images were all in good correspondence with the confirming bioluminescence images in respect to signal colocalization. Fluorescence imaging detected all tumors and successfully guided total tumor excision by effectively detecting small tumor residuals, which occasionally were missed by the surgeon. Tumor tissue exhibited target-to-background ratio of ~4.0, which was significantly higher compared with white-light images representing the visual contrast. Histopathology confirmed the capability of the method to identify tumor negative margins with high specificity and better prediction rate compared with visual inspection. CONCLUSIONS: Real-time multispectral fluorescence imaging using tumor specific molecular probes is a promising modality for tumor excision by offering real time feedback to the surgeon in the operating room.
AU  - Themelis, G.
AU  - Harlaar, N.J.
AU  - Kelder, W.*
AU  - Bart, J.*
AU  - Sarantopoulos, A.
AU  - van, Dam, G.M.*
AU  - Ntziachristos, V.
C1  - 6202
C2  - 28565
SP  - 3506-3513
TI  - Enhancing surgical vision by using real-time imaging of αvβ3-integrin targeted near-infrared fluorescent agent.
JO  - Ann. Surg. Oncol.
VL  - 18
IS  - 12
PB  - Society of Surgical Oncology
PY  - 2011
SN  - 1068-9265
ER  - 

TY  - JOUR
AB  - BACKGROUND: Histone deacetylases (HDACs) modulate chromatin and may influence the effect of DNA-damaging drugs. We investigated HDAC1 and -2 expression in gastric carcinomas (GCs) for an association of patient outcome with conventional neoadjuvant chemotherapy. In vitro, HDAC inhibitors were evaluated as alternative treatment options. METHODS: HDAC1/2 expression was analyzed immunohistochemically in 127 pretherapeutic biopsy samples of neoadjuvant (platinum/5-fluorouracil) chemotherapy-treated GC patients and correlated with response and overall survival (OS). Chemosensitivity of four GC cell lines to cisplatin and the HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and valproic acid was determined by XTT assays. Efficiencies of combined drug schedules were analyzed. RESULTS: High expression of HDAC1/2 was found in 69 (54%) of 127 and 108 (85%) of 127 carcinomas, respectively, and was not associated with response or OS. In patients whose disease responded to therapy, high HDAC1 expression was associated with worse OS (P = 0.005). In cell lines, sequential treatment with SAHA and cisplatin showed synergistic effects irrespective of the initial cisplatin sensitivity. CONCLUSIONS: HDAC1 and -2 expression is not suitable to predict response or survival for neoadjuvant-treated GC patients, but HDAC1 expression may be used for risk stratification in patients whose disease responds to therapy. Sequential treatment with SAHA and cisplatin may represent an alternative treatment option for GC patients.
AU  - Mutze, K.*
AU  - Langer, R.*
AU  - Becker, K.*
AU  - Ott, K.*
AU  - Novotny, A.*
AU  - Luber, B.*
AU  - Hapfelmeier, A.*
AU  - Göttlicher, M.
AU  - Höfler, H.
AU  - Keller, G.*
C1  - 687
C2  - 27248
SP  - 3336-3343
TI  - Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
JO  - Ann. Surg. Oncol.
VL  - 17
IS  - 12
PB  - Springer
PY  - 2010
SN  - 1068-9265
ER  -